National utilization patterns of warfarin use in older patients with atrial fibrillation: A population-based study of medicare part D beneficiaries

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 35-42

  Raji, Mukaila A ^a   Lowery, Matthew ^b   Lin, Yu Li ^b   Kuo, Yong Fang ^b   Baillargeon, Jacques ^b   Goodwin, James S ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UTMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGED; ARTICLE; CARDIOLOGIST; CHADS2 SCORE; COHORT ANALYSIS; COMORBIDITY; DRUG UTILIZATION; ETHNICITY; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LINEAR MODELS; MALE; MEDICARE PART D; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; STROKE; UNITED STATES; WARFARIN;

EID: 84872973720     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R515     Document Type: Article

References (36)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2011;123:e18-e209.
2. Lip G Y, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648-661. doi: 10.1016/S0140-6736(11)61514-61516
3. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
4. Meschia JF, Merril P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke 2010;41:581-587.
5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-125.
6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146:857-867.
8. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:10704.
9. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;3:CD001927.
10. Fuster V, Ryden LE, Cannom DS, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2011;123:e269-e367.
11. Srivastava A, Hudson M, Hamoud I, Cavalcante J, Pai C, Kaatz S. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008;6:6.
12. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005;21:1583-1594.
13. Weisbord SD, Whittle J, Brooks RC. Is warfarin really underused in patients with atrial fibrillation? J Gen Intern Med 2001;16:743-749.
14. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby J V, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999;131:927-934.
15. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46.
16. Fang MC, Go AS, Hylek EM, et al. Age and risk of warfarin-associated hemorrhage: the Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc 2006;54:1231-1236.
17. Fang MC, Go AS, Hylek EM, et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118: 612-617.
18. Man-Son-Hing M, Laupacis A. Balancing risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 2002;162:541-550.
19. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Inten Med 2007;167:1414-1419.
20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
21. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
23. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-145.
24. Howard G, Cushman M, Prineas RJ, et al. Advancing the hypothesis that geographic variations in risk factors contribute relatively little to observed geographic variations in heart disease and stroke mortality. Prev Med 2009;49:129-132.
25. Cushman M, Cantrell RA, McClure LA, et al. Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol 2008;64:507-513.
26. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-2541.
27. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
28. The Dartmouth Atlas of Health Care. Zip code crosswalk files of 2007. http://www.dartmouthatlas.org/tools/downloads.aspx (accessed 2011 Jun 7).
29. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-752.
30. Liao Y, Greenlund KJ, Croft JB, Keenan NL, Giles WH. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke 2009;40:3336-3341.
31. Zweifler RM, McClure LA, Howard VJ, et al. Racial and geographic differences in prevalence, awareness, treatment and control of dyslipidemia: the reasons for geographic and racial differences in stroke (REGARDS) study. Neuroepidemiology 2011;37:39-44.
32. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-1233.
33. Freeman J V, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
34. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
35. Olesen JB, Lip G Y, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. doi: 10.1136/bmj.d124
36. Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860-865.